Guido Reifenberger
Genetics · 2002–2021
A researcher in the Science corpus: 29 papers; trusts 3 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Genetics — 363 citations into it
Whom Guido Reifenberger trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Guido Reifenberger overall
Papers from Guido Reifenberger's perspective
Ordered by how strongly the researchers Guido Reifenberger trusts endorse each paper. Same corpus, a different order for every researcher.
- Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. (Cancer Cell)
- Analysis of the IDH1 codon 132 mutation in brain tumors (Acta Neuropathologica)
- MGMT gene silencing and benefit from temozolomide in glioblastoma. (New England Journal of Medicine)
- IDH1 and IDH2 mutations in gliomas. (New England Journal of Medicine)
- Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma (Nature)
- Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. (Cancer Cell)
- MethyLight: a high-throughput assay to measure DNA methylation. (Nucleic Acids Research)
- Consensus Clustering: A Resampling-Based Method for Class Discovery and Visualization of Gene Expression Microarray Data (Machine-mediated learning)
- IDH1 and IDH2 Mutations in Gliomas (New England Journal of Medicine)
- Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. (New England Journal of Medicine)
Their papers
- International network of cancer genome projects (2010) — 2,229 citations
- Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma (2012) — 2,412 citations
- MGMT promoter methylation in malignant gliomas: ready for personalized medicine? (2010) — 766 citations
- Dissecting the genomic complexity underlying medulloblastoma (2012) — 847 citations
- DNA methylation-based classification of central nervous system tumours (2018) — 2,473 citations
- The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. (2021) — 9,662 citations
- EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood (2020) — 1,588 citations
- LONGITUDINAL MOLECULAR TRAJECTORIES OF DIFFUSE GLIOMA IN ADULTS (2019) — 446 citations
- cIMPACT-NOW Update 3: Recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV” (2018) — 744 citations
- Advances in the molecular genetics of gliomas — implications for classification and therapy (2017) — 596 citations
- European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. (2017) — 945 citations
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary (2016) — 14,109 citations
- New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs (2016) — 819 citations
- Glioblastoma: pathology, molecular mechanisms and markers (2015) — 634 citations
- Glioma (2015) — 603 citations
- Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma (2014) — 614 citations
- EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. (2014) — 704 citations
- Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition (2014) — 693 citations
- Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma (2013) — 747 citations
- Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. (2012) — 1,021 citations